Literature DB >> 14555520

Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards.

Vassilis L Souliotis1, Meletios A Dimopoulos, Petros P Sfikakis.   

Abstract

PURPOSE: To investigate the possibility of measuring the gene-specific DNA damage after therapeutic exposure to nitrogen mustards and to examine its relationship with the clinical response. EXPERIMENTAL
DESIGN: The kinetics of gene-specific monoadducts and interstrand cross-link formation/repair were measured in the p53 and N-ras genes. DNA extracted from human peripheral lymphocytes following in vitro exposure to melphalan or therapeutic exposure to melphalan or cyclophosphamide was used.
RESULTS: When lymphocytes were treated in vitro with biologically relevant doses of melphalan, monoadducts accumulated rapidly in both p53 and N-ras genes, reaching maximal levels within 2 h, whereas the highest interstrand cross-link levels were found within 8 h. Thereafter, the adducts were repaired with half-lives of 14.5 +/- 0.3 h (p53) or 18.8 +/- 1.5 h (N-ras) for monoadducts and 12.4 +/- 0.8 h (p53) or 14.1 +/- 2.2 h (N-ras) for interstrand cross-links. Moreover, peak levels of monoadducts in both genes were observed 2 h after treatment in peripheral leukocytes from patients with multiple myeloma treated with high-dose i.v. melphalan, supported by autologous stem cell transplantation, whereas interstrand cross-links were maximal within 8 h. Of seven patients examined, the three who showed the least levels of DNA damage did not respond to the high-dose melphalan.
CONCLUSIONS: This is the first report showing that it is feasible to measure gene-specific DNA damage in a readily accessible tissue of humans exposed to bifunctional alkylating drugs and to examine, at the level of the individual patient, the relationships between the induction/repair of cytotoxic DNA damage and clinical response or long-term complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555520

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

2.  Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.

Authors:  Dimitra T Stefanou; Hara Episkopou; Soterios A Kyrtopoulos; Aristotelis Bamias; Maria Gkotzamanidou; Christina Bamia; Christina Liakou; Margarita Bekyrou; Petros P Sfikakis; Meletios-Athanasios Dimopoulos; Vassilis L Souliotis
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

3.  The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.

Authors:  Qing Chen; Pieter C Van der Sluis; David Boulware; Lori A Hazlehurst; William S Dalton
Journal:  Blood       Date:  2005-03-31       Impact factor: 22.113

4.  Formation of cyclophosphamide specific DNA adducts in hematological diseases.

Authors:  L'Aurelle A Johnson; Bhaskar Malayappan; Natalia Tretyakova; Colin Campbell; Margaret L MacMillan; John E Wagner; Pamala A Jacobson
Journal:  Pediatr Blood Cancer       Date:  2011-07-25       Impact factor: 3.167

5.  Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.

Authors:  Ping Zhou; Julie Teruya-Feldstein; Ping Lu; Martin Fleisher; Adam Olshen; Raymond L Comenzo
Journal:  Blood       Date:  2007-11-02       Impact factor: 22.113

6.  DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

Authors:  Maria Gkotzamanidou; Evangelos Terpos; Christina Bamia; Nikhil C Munshi; Meletios A Dimopoulos; Vassilis L Souliotis
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

7.  Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

Authors:  David C Johnson; Sophie Corthals; Christine Ramos; Antje Hoering; Kim Cocks; Nicholas J Dickens; Jeff Haessler; Harmut Goldschmidt; J Anthony Child; Sue E Bell; Graham Jackson; Dalsu Baris; S Vincent Rajkumar; Faith E Davies; Brian G M Durie; John Crowley; Pieter Sonneveld; Brian Van Ness; Gareth J Morgan
Journal:  Blood       Date:  2008-09-19       Impact factor: 22.113

8.  Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.

Authors:  Maria Gkotzamanidou; Dimitrios Christoulas; Vasillis L Souliotis; Athanasios Papatheodorou; Meletios A Dimopoulos; Evangelos Terpos
Journal:  Med Sci Monit       Date:  2013-12-20

9.  A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes.

Authors:  Maia van Kan; Kathryn E Burns; Nuala A Helsby
Journal:  Cancer Chemother Pharmacol       Date:  2021-08-04       Impact factor: 3.333

10.  Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Authors:  M Gkotzamanidou; P P Sfikakis; S A Kyrtopoulos; C Bamia; M A Dimopoulos; V L Souliotis
Journal:  Br J Cancer       Date:  2014-07-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.